Swedish Orphan Biovitrum AB (publ) holds the cleaner structural position, with the lead spread across growth and stability. Evotec SE still has the edge on valuation, which keeps the comparison from looking entirely one-sided. On the market side, Swedish Orphan Biovitrum AB (publ) is in better shape — its trend is intact while Evotec SE's trend has broken down. That puts structure and market broadly in agreement — Swedish Orphan Biovitrum AB (publ)'s lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (EVT.DE: HDAX, SOBI.ST: STOXX 600).
This is not just a one-metric split: both growth and stability materially support the lead. Swedish Orphan Biovitrum AB (publ) leads by 24 points on the overall comparison score.
Both operate in: Drug Manufacturers - Specialty & Generic
This comparison is based on industry proximity, not on functional trajectory similarity. EVT.DE and SOBI.ST share the same industry classification.
For a similarity-based comparison, see how Evotec SE and SOBI.ST each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Swedish Orphan Biovitrum AB (publ) is cheaper, but Evotec SE is still stronger.
Valuation position uses peer-relative valuation score and peer-relative PE percentile (idx_pct_pe) where available.
Where EVT.DE and SOBI.ST each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
One company is still expanding while the other is contracting, which creates a very wide growth split.
Evotec SE still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.
The lead is built on both growth and stability — though valuation still provides a counterweight.
Break down the EVT.DE vs SOBI.ST comparison across all dimensions with the full interactive tool.
Explore how EVT.DE and SOBI.ST each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.